Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cardiff Oncology (CRDF) Non-Current Assets (2016 - 2025)

Historic Non-Current Assets for Cardiff Oncology (CRDF) over the last 16 years, with Q3 2025 value amounting to $2.0 million.

  • Cardiff Oncology's Non-Current Assets fell 4447.25% to $2.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $8.3 million, marking a year-over-year decrease of 4723.18%. This contributed to the annual value of $2.1 million for FY2024, which is 4944.38% down from last year.
  • Cardiff Oncology's Non-Current Assets amounted to $2.0 million in Q3 2025, which was down 4447.25% from $2.0 million recorded in Q2 2025.
  • Cardiff Oncology's 5-year Non-Current Assets high stood at $4.9 million for Q4 2022, and its period low was $863000.0 during Q2 2021.
  • In the last 5 years, Cardiff Oncology's Non-Current Assets had a median value of $3.6 million in 2024 and averaged $3.3 million.
  • Its Non-Current Assets has fluctuated over the past 5 years, first soared by 34577.06% in 2022, then tumbled by 4944.38% in 2024.
  • Over the past 5 years, Cardiff Oncology's Non-Current Assets (Quarter) stood at $3.4 million in 2021, then soared by 43.61% to $4.9 million in 2022, then decreased by 13.9% to $4.2 million in 2023, then crashed by 49.44% to $2.1 million in 2024, then dropped by 7.35% to $2.0 million in 2025.
  • Its Non-Current Assets stands at $2.0 million for Q3 2025, versus $2.0 million for Q2 2025 and $2.1 million for Q1 2025.